New Risk • Apr 22
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$124k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.1m free cash flow). Share price has been highly volatile over the past 3 months (72% average daily change). Negative equity (-US$124k). Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Revenue is less than US$1m (US$147k revenue). Market cap is less than US$10m (₪12.8m market cap, or US$4.25m). New Risk • Apr 20
New major risk - Revenue and earnings growth Earnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (72% average daily change). Earnings have declined by 0.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Revenue is less than US$1m (US$247k revenue). Market cap is less than US$10m (₪12.8m market cap, or US$4.30m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Reported Earnings • Apr 19
Full year 2025 earnings released: US$0.21 loss per share (vs US$89.83 loss in FY 2024) Full year 2025 results: US$0.21 loss per share (improved from US$89.83 loss in FY 2024). Revenue: US$147.0k (down 16% from FY 2024). Net loss: US$2.90m (loss narrowed 45% from FY 2024). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Annonce • Jan 21
NextFerm Technologies Ltd, Annual General Meeting, Feb 25, 2026 NextFerm Technologies Ltd, Annual General Meeting, Feb 25, 2026. Location: pearl law offices, Israel Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent External Director Suzana Nahum-Zilberberg was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Apr 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.5m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m (US$174k revenue). Market cap is less than US$10m (₪7.87m market cap, or US$2.07m). Reported Earnings • Apr 02
Full year 2024 earnings released: US$0.90 loss per share (vs US$0.94 loss in FY 2023) Full year 2024 results: US$0.90 loss per share. Net loss: US$5.32m (loss widened 25% from FY 2023). New Risk • Mar 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 2.4% per year over the past 5 years. Revenue is less than US$1m (US$110k revenue). Market cap is less than US$10m (₪12.2m market cap, or US$3.39m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). New Risk • May 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.7m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m (US$283k revenue). Market cap is less than US$10m (₪27.8m market cap, or US$7.57m). Minor Risk Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Reported Earnings • Apr 01
Full year 2023 earnings released: US$0.06 loss per share (vs US$0.54 loss in FY 2022) Full year 2023 results: US$0.06 loss per share (improved from US$0.54 loss in FY 2022). Net loss: US$4.25m (loss narrowed 47% from FY 2022). New Risk • Mar 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.2m free cash flow). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (US$384k revenue). Market cap is less than US$10m (₪20.9m market cap, or US$5.82m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.6% average weekly change). Reported Earnings • Aug 22
First half 2023 earnings released: US$0.04 loss per share (vs US$0.23 loss in 1H 2022) First half 2023 results: US$0.04 loss per share (improved from US$0.23 loss in 1H 2022). Net loss: US$2.29m (loss narrowed 34% from 1H 2022). Reported Earnings • Mar 26
Full year 2022 earnings released: US$0.54 loss per share (vs US$0.49 loss in FY 2021) Full year 2022 results: US$0.54 loss per share (further deteriorated from US$0.49 loss in FY 2021). Net loss: US$8.07m (loss widened 47% from FY 2021). Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Suzana Nahum-Zilberberg was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Suzana Nahum-Zilberberg was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$0.49 (up from US$1.87 loss in FY 2020). Net loss: US$5.51m (loss widened 37% from FY 2020). Revenue was in line with analyst estimates. Annonce • Jul 15
NextFerm Technologies Ltd Obtains Regulatory Approval to Market Astaferm Astaxanthin Antioxidant in Canada NextFerm Technologies Ltd. announced that Health Canada has granted a regulatory marketing approval for Astaferm(R), its innovative fermented astaxanthin antioxidant in the form of Gummies. This is the only fermented astaxanthin with no odor and flavor. Along with the receipt of Astaferm(R)'s license approval (NPN - Natural Product Number), the company is preparing for the launch of several applications of Astaferm(R) in North America, including for Immunity support, which is a growing segment due to the Covid-19 pandemic. The Company has already supplied initial quantities of Astaferm(R) in Canada and is currently in dialogues with potential customers. Astaferm(R) has a US Self GRAS regulatory approval and was launched in the US at the end of 2020. The product is in early stages of sales, by well-known US dietary supplement brands, such as Carlson Labs and Purity Products. Since Astaferm(R) is flavorless and odorless, the Gummies application constitutes a significant differentiation from other astaxanthin products available on the market, produced from algae with fishy odor, and therefore applied mainly in soft-gels. NextFerm currently prepares to expand the marketing of Astaferm(R) for additional indications such as immune system support, as well as expanding into additional serving forms, such as water-dispersible powder for food and beverages, and fermented Astaferm(R) oil for soft-gels with competitive pricing. 
